Agios Pharmaceuticals | AGIO - Loan Capital


Agios Pharmaceuticals reported $1.06M in Loan Capital for its fiscal quarter ending in September of 2022.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
Astellas Pharma JPY 320B 0 Dec/2025
AstraZeneca USD 6.55B 19.43B Sep/2025
Bayer EUR 32.71B 1B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Incyte USD 35.37M 3.61M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 26M 6M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025